Li Yuefeng, Li Zhian
Department of Oncological Surgery, Shaoxing Second Hospital, Shaoxing, China.
Front Oncol. 2021 Mar 18;11:629614. doi: 10.3389/fonc.2021.629614. eCollection 2021.
Breast cancer incidence and mortality rates have been consistently high among women. The use of diverse therapeutic strategies, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, has improved breast cancer prognosis. However, drug resistance has become a tremendous obstacle in overcoming breast cancer recurrence and metastasis. It is known that mitochondria play an important role in carcinoma cell growth, invasion and apoptosis. Recent studies have explored the involvement of mitochondrial metabolism in breast cancer prognosis. Here, we will provide an overview of studies that investigated mitochondrial metabolism pathways in breast cancer treatment resistance, and discuss the application prospects of agents targeting mitochondrial pathways against drug-resistant breast cancer.
J Hematol Oncol. 2022-7-18
Biochim Biophys Acta Bioenerg. 2017-2-1
Adv Exp Med Biol. 2007
J Exp Clin Cancer Res. 2019-1-23
Drug Resist Updat. 2017-8-19
Cancers (Basel). 2023-3-23
Drug Dev Res. 2015-11
Biochem Pharmacol. 2020-4-7
Metabolites. 2025-6-23
Nat Chem Biol. 2025-6
Int J Mol Sci. 2024-5-2
Cancers (Basel). 2022-11-22
Cancers (Basel). 2020-9-8
J Colloid Interface Sci. 2020-1-14
Prog Biophys Mol Biol. 2020-3
Cancer Res. 2019-10-3
Expert Opin Ther Pat. 2019-10-14